TerminatedPhase 2
Extension Study of Participants From SPG302-ALS-001
Reason given: patients treated through compassionate use program
Key facts
- Where
- Adelaide, Herston, and North Ryde, AustraliaSee the 3 sites
- Phase
- Phase 2
Where in Australia
- Flinders Medical centerAdelaide, AustraliaNo longer taking part
- Royal Brisbane and Women's HospitalHerston, AustraliaNo longer taking part
- Macquarie UniversityNorth Ryde, AustraliaNo longer taking part
Trial details
- Who runs it
- Spinogenix
- Trial code
- NCT06903286
- Record updated
- 17 December 2025
- Original description
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)Read full original descriptionShow less
An Open-label Extension of SPG302-ALS-001 Study to Evaluate the Long-term Safety and Efficacy of Daily Oral SPG302 Treatment in Participants With Amyotrophic Lateral Sclerosis
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
Inclusion: Must have participated in all study activities of SPG302-ALS-001, the parent study.
Exclusion: Unable to reliably and regularly swallow whole oral medications on a daily basis; Medical conditions that investigator or sponsor determine would interfere with participation in clinical trial.